Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial

BACKGROUND: Second-line treatment options for small cell lung cancer (SCLC) are limited. Preclinical research shows that inhibition of poly (ADP-ribose) polymerase (PARP) could upregulate programmed death-ligand 1 (PD-L1), and thus render cancer cells more sensitive to immune checkpoint inhibitors....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yanjun, Huang, Zhiyu, Fang, Jian, Liu, Anwen, Lu, Hongyang, Yu, Xinmin, Chen, Kaiyan, Xu, Xiaoling, Ma, Xinjing, Shi, Wei, Kim, Young Hak, Hakozaki, Taiki, Addeo, Alfredo, Shen, Yu, Li, Shaorong, Fan, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271434/
https://www.ncbi.nlm.nih.gov/pubmed/35832454
http://dx.doi.org/10.21037/tlcr-22-356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271434/
https://www.ncbi.nlm.nih.gov/pubmed/35832454
http://dx.doi.org/10.21037/tlcr-22-356

Ejemplares similares